Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ.

N Engl J Med. 2002 Dec 26;347(26):2104-10.

2.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
3.

Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.

Naesdal J, Wilson I.

Eur J Gastroenterol Hepatol. 2001 Dec;13(12):1401-6. Review.

PMID:
11742186
4.
5.
6.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

7.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
8.

Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.

Howden CW.

Am J Health Syst Pharm. 1999 Dec 1;56(23 Suppl 4):S5-11. Review. Erratum in: Am J Health Syst Pharm 2000 Apr 1;57(7):699.

PMID:
10597118
9.

COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?

Simon LS.

Gastroenterol Clin North Am. 2001 Dec;30(4):1011-25, viii. Review.

PMID:
11764530
10.

Helicobacter pylori infection and the use of NSAIDs.

Bazzoli F, De Luca L, Graham DY.

Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):775-85. Review.

PMID:
11566040
11.

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.

Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL.

Pharmacoeconomics. 2001;19 Suppl 1:33-47. Review.

PMID:
11280104
13.

The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.

Maddrey WC, Maurath CJ, Verburg KM, Geis GS.

Am J Ther. 2000 May;7(3):153-8. Review. Erratum in: Am J Ther 2000 Sep;7(5):341.

PMID:
11317164
16.

[COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].

Peretz A.

Rev Med Brux. 2001 Sep;22(4):A377-80. Review. French.

PMID:
11680204
17.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
18.
19.

Cyclooxygenase inhibition: between the devil and the deep blue sea.

Hawkey CJ.

Gut. 2002 May;50 Suppl 3:III25-30. Review.

20.

Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.

Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K.

J Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:8-12. doi: 10.1111/j.1440-1746.2012.07071.x. Review.

PMID:
22486865

Supplemental Content

Support Center